Neurocognitive deficits following pediatric brain tumor treatment
Key Mechanisms
Impact of somatic genetic variants in DNA repair genes on IQ outcomes post-treatment involving DNA damaging agents (radiation, chemotherapy)
Target Population
Children and adolescents (0–19 years) treated for brain tumors
Care Setting
Pediatric oncology and neurocognitive follow-up clinics
Key Highlights
Pediatric brain tumor survival has improved, increasing focus on long-term neurocognitive deficits.
Genetic variants in DNA repair genes may influence IQ outcomes after treatment with radiation and chemotherapy.
Clinical risk factors for neurocognitive deficits include younger age at diagnosis, sex, hydrocephalus, tumor location, and socioeconomic factors.
Guideline-Based Recommendations
Diagnosis
Perform routine neurocognitive assessment using standardized IQ testing (e.g., Wechsler Intelligence Scale for Children) during follow-up.
Consider genetic testing for DNA repair gene variants to identify patients at risk for neurocognitive decline.
Management
Stratify treatment plans based on risk factors including genetic markers to minimize neurocognitive impact.
Implement early cognitive interventions for patients identified as high risk for neurocognitive deficits.
Monitoring & Follow-up
Conduct serial neurocognitive evaluations to monitor changes in IQ over time post-treatment.
Monitor patients longitudinally for neurocognitive outcomes, especially those with identified genetic risk factors.
Risks
Radiation dose and volume, especially craniospinal irradiation, increase risk of neurocognitive deficits.
Younger age at diagnosis and tumor location (posterior fossa) are associated with worse neurocognitive outcomes.
Genetic abnormalities such as neurofibromatosis type-1 and socioeconomic factors contribute to risk.
Patient & Prescribing Data
46 pediatric brain tumor survivors treated with surgery, chemotherapy, and photon radiation therapy
Genotyping revealed associations between specific SNPs in DNA repair genes and IQ outcomes, suggesting potential for personalized treatment and monitoring strategies.
Clinical Best Practices
Exclude patients with pre-existing neurocognitive deficits when assessing treatment impact.
Use SNP genotyping to identify genetic variants that may predict neurocognitive outcomes.
Apply statistical models incorporating allele status and radiation type to evaluate neurocognitive risk.
Match patient cohorts by age, sex, and time from treatment to IQ testing for accurate comparative analysis.
Consider tumor location and diagnosis subtype when evaluating neurocognitive prognosis.
by Sydney T. Grob, Kristen R. Miller, Bridget Sanford, Andrew M. Donson, Kenneth Jones, Andrea M. Griesinger, Vladimir Amani, Nicholas K. Foreman, Arthur Liu, Michael Handler, Todd C. Hankinson, Sarah Milgrom, Jean M. Mulcahy Levy
